Abstract Number: 605 • 2013 ACR/ARHP Annual Meeting
Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India
Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to…Abstract Number: 2724 • 2013 ACR/ARHP Annual Meeting
cAMP Responsive Element Modulator (CREM)α Governs CD8 Expression and Contributes to the Generation of CD3+CD4–CD8– T Cells in Lupus
Background/Purpose: CD3+CD4-CD8- "double negative" T cells are expanded in the peripheral blood of patients with systemic lupus erythematosus (SLE) and lupus-prone mice. Double negative T…Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting
IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting
The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting
Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…Abstract Number: 2701 • 2013 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling
Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution…Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting
GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…Abstract Number: 610 • 2013 ACR/ARHP Annual Meeting
Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?
Background/Purpose: Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive…Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…Abstract Number: 1070 • 2013 ACR/ARHP Annual Meeting
Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus
Background/Purpose: Belimumab is a B lymphocyte stimulator-specific inhibitor approved for treatment of systemic lupus erythematosus (SLE). The purpose of the study was to describe medication…Abstract Number: 562 • 2013 ACR/ARHP Annual Meeting
The Knock-Out Of TWEAK Receptor/Fn14 Ameliorates Lupus Nephritis In MRL/Lpr Mice
Background/Purpose: Renal mesangial cells, podocytes, and tubular cells express Fn14, the sole confirmed receptor for the tumor necrosis factor (TNF)-family member cytokine TWEAK (TNF-like weak…Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- Next Page »